Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status Not Available
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 42291-779; 67877-259; 47781-690; 0093-3061; 67877-260; 42291-780; 47781-683; 42571-220; 16714-771; 16714-770; 0093-3060; 42571-221
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Orthostatic hypotension24.06.03.004; 17.05.01.0200.044652%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Parkinsonism17.01.05.0030.007442%Not Available
Peritonitis11.01.07.007; 07.19.05.0040.007442%
Personality change19.05.01.006; 17.02.05.0190.007442%
Pneumonia22.07.01.003; 11.01.09.0030.012619%Not Available
Pneumonia aspiration22.01.01.0050.001941%Not Available
Presyncope02.01.02.007; 17.02.05.009; 24.06.02.0100.007442%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.007442%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.0030.007442%Not Available
Rhabdomyolysis15.05.05.0020.007442%
Seizure17.12.03.0010.014884%
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.037210%Not Available
Sleep disorder19.02.04.0010.007442%Not Available
Somnolence19.02.05.003; 17.02.04.0060.033489%
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.007442%Not Available
Subarachnoid haemorrhage12.01.10.011; 24.07.04.004; 17.08.01.0100.003883%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.022326%
Transient ischaemic attack24.04.06.005; 17.08.04.0010.007442%
Tremor17.01.06.0020.033489%
Urinary tract infection11.01.14.004; 20.08.02.001--
Vertigo17.02.12.002; 04.04.01.0030.007442%
Vomiting07.01.07.003--
Weight decreased13.15.01.0050.018605%
White blood cell count decreased13.01.06.0120.011163%
Withdrawal syndrome08.06.02.012; 19.07.02.0050.007442%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages